Healthcare Industry News: Biostat
News Release - January 18, 2011
CardioDX Uses Revolution Analytics to Develop First Non-Intrusive Test for Predicting Coronary Artery DiseaseScientists Use Revolution R to Develop Corus CAD® Test, Recognized as One of “Top Ten Medical Breakthroughs of 2010” by TIME Magazine
PALO ALTO, Calif.--(Healthcare Sales & Marketing Network)-- Revolution Analytics, the leading provider of commercial software and support for the popular open source R statistics language, today announced the successful implementation of its signature product, Revolution R Enterprise, by Biostatisticians at CardioDX, a genomic research firm. Revolution R was used to design the Corus CAD® test, the first test of its kind to analyze genomic data and identify at-risk patients for coronary artery disease (CAD) without requiring an invasive procedure. The Corus CAD® test was recently honored as one of TIME Magazine’s “Top Ten Medical Breakthroughs of 2010”.
Revolution R was used to help develop the algorithm that powers the Corus CAD® test. To do so, Biostatisticians at CardioDX analyzed over 10 gigabytes of genomic data to ultimately identify 23 predictive genes for CAD. In addition to using open source R, Biostatisticians at CardioDX employ Revolution R in their daily research, citing its unparalleled flexibility and power for analyzing large and complex data sets in R.
“Analyzing clinical data from thousands of patients poses a serious analytical challenge,” said Michael Elashoff, Director of Biostatistics at CardioDX. “We rely on R for nearly all of our research projects because it allows us to run accurate and effective analyses. Revolution R offers even greater speed than open source R and allowed us to run analyses for the Corus CAD® faster than we could with any alternative. This was especially beneficial for us considering the fact that it took over one million separate analyses to develop this algorithm.”
Revolution R Enterprise continues to be the premier production-grade analytics software built for advanced R statistics computing. The flagship product features higher performance, greater scalability and stronger reliability to R at a fraction of the cost of legacy products.
“R is used heavily by life sciences companies that perform advanced biological research–scientists know R and are comfortable working with it,” said Revolution Analytics COO Jeff Erhardt. “We’ve seen strong growth in this sector over the past year. Seeing such wide adoption of Revolution R complement these research endeavors is a testament to its ability to execute complex tasks with even greater speed than open source R.”
About Revolution Analytics
Revolution Analytics (www.revolutionanalytics.com) delivers advanced analytics software at half the cost of existing solutions. By building on open source R—the world’s most powerful statistics software—with innovations in big data analysis, integration and user experience, Revolution Analytics meets the demands and requirements of modern data-driven businesses. Headquartered in Palo Alto, Calif., Revolution Analytics is backed by North Bridge Venture Partners and Intel Capital.
CardioDX, Inc., a pioneer in the field of cardiovascular genomic diagnostics, is committed to developing clinically validated tests that empower clinicians to better tailor care to each individual patient. Strategically focused on coronary artery disease, cardiac arrhythmia and heart failure, CardioDX is poised to expand patient access and improve healthcare quality and efficiency through the commercialization of genomic technologies. In 2010, the company was honored as a winner of the Wall Street Journal’s prestigious Technology Innovation Awards and one of TIME Magazine’s Top Ten Medical Breakthroughs. Privately held, CardioDX is funded by Kleiner, Perkins, Caufield & Byers, TPG Biotech, Mohr Davidow Ventures, Intel Capital, Pappas Ventures, DAG Ventures, Asset Management Company and GE Capital. For more information, please visit www.cardiodx.com.
Source: Revolution Analytics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.